Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus paclitaxel in CDK4/6 pathway–activated tumors
KCT0005293Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in Nonhematologic neoplasms, sponsored by Eli Lilly and Company. Started Feb 2021; status: completed.
02
Drugs
abemaciclib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on KCT0005293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005293.